title: Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN.
abstract: Glioblastoma multiforme (GBM) is the most aggressive brain tumour in adults and remains incurable despite multimodal intensive treatment regimens. We present a patient with a recurrent glioblastoma who showed coexpression of the epidermal growth factor receptor mutant variant III (EGFRvIII) and the tumour-suppressor protein PTEN. She was treated with the tyrosine kinase inhibitor erlotinib for four months, achieving a partial response with improvement of neurologic symptoms. A review of the pertinent literature supporting the future use of therapies against epidermal growth factor receptor (EGFR) in highgrade gliomas is also provided.
authors.affiliation: Medical Oncology Department, Hospital Universitario Clínico San Carlos, Madrid, Spain. anabelencustodio@hotmail.com
authors.forename: A
authors.initials: A
authors.lastname: Custodio
authors.forename: A
authors.initials: A
authors.lastname: Calles
authors.forename: P
authors.initials: P
authors.lastname: Pérez-Segura
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D003131:Combined Modality Therapy; D066246:ErbB Receptors / Q000096:biosynthesis* / Q000235:genetics; D000069347:Erlotinib Hydrochloride; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D006044:Goiter, Nodular / Q000150:complications; D006801:Humans; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D051059:PTEN Phosphohydrolase / Q000096:biosynthesis* / Q000235:genetics; D011799:Quinazolines / Q000627:therapeutic use*; D011878:Radiotherapy
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; C410723:epidermal growth factor receptor VIII; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human
references.citation: N Engl J Med. 2004 Sep 16;351(12):1260-1; author reply 1260-1
references.pmid: 15376352
references.citation: Lancet. 2003 Jul 5;362(9377):62-4
references.pmid: 12853203
references.citation: Science. 2002 Jul 5;297(5578):63-4
references.pmid: 12098689
references.citation: Radiother Oncol. 2004 Sep;72(3):267-73
references.pmid: 15450724
references.citation: J Clin Oncol. 2004 Jan 1;22(1):133-42
references.pmid: 14638850
references.citation: Science. 2004 Aug 20;305(5687):1163-7
references.pmid: 15284455
references.citation: Brain Tumor Pathol. 1998;15(1):53-7
references.pmid: 9879464
references.citation: Cancer Chemother Pharmacol. 2012 Jun;69(6):1507-18
references.pmid: 22392572
references.citation: Genes Dev. 2003 Dec 15;17(24):2998-3010
references.pmid: 14701871
references.citation: Neuro Oncol. 2006 Jan;8(1):67-78
references.pmid: 16443950
references.citation: Mol Cell Biol. 2008 Jan;28(2):587-600
references.pmid: 18025104
references.citation: Oncogene. 2004 Jun 3;23(26):4594-602
references.pmid: 15077177
references.citation: Brain Tumor Pathol. 2004;21(2):53-6
references.pmid: 15700833
references.citation: Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12867-72
references.pmid: 17646646
references.citation: Clin Cancer Res. 2002 May;8(5):1100-6
references.pmid: 12006525
references.citation: Cancer Res. 2002 Jan 1;62(1):200-7
references.pmid: 11782378
references.citation: Science. 2007 Oct 12;318(5848):287-90
references.pmid: 17872411
references.citation: Science. 2003 Apr 18;300(5618):445-52
references.pmid: 12702867
references.citation: Gene. 2006 Jun 7;374:1-9
references.pmid: 16675164
references.citation: J Neuropathol Exp Neurol. 2004 Jul;63(7):700-7
references.pmid: 15290895
references.citation: Pathol Oncol Res. 2009 Jun;15(2):225-9
references.pmid: 18752056
references.citation: J Clin Oncol. 2009 Feb 1;27(4):579-84
references.pmid: 19075262
references.citation: Oncogene. 2004 Aug 12;23(36):6095-104
references.pmid: 15221011
references.citation: Anticancer Res. 2008 Nov-Dec;28(6A):3729-32
references.pmid: 19189657
references.citation: Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10314-9
references.pmid: 11504908
references.citation: Cancer Res. 2007 Jun 15;67(12):5779-88
references.pmid: 17575145
references.citation: Oncogene. 2003 May 8;22(18):2812-22
references.pmid: 12743604
references.citation: Clin Cancer Res. 2003 Jun;9(6):2316-26
references.pmid: 12796401
references.citation: Cancer Res. 2003 Jun 1;63(11):2742-6
references.pmid: 12782577
references.citation: J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56
references.pmid: 11504770
references.citation: Br J Cancer. 2002 May 6;86(9):1518-23
references.pmid: 11986789
references.citation: N Engl J Med. 2004 May 20;350(21):2129-39
references.pmid: 15118073
references.citation: Mol Cancer Ther. 2005 Jan;4(1):101-12
references.pmid: 15657358
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1268-74
references.pmid: 19204207
references.citation: N Engl J Med. 2005 Nov 10;353(19):2012-24
references.pmid: 16282176
references.citation: Neurology. 2005 Apr 26;64(8):1444-5
references.pmid: 15851741
references.citation: N Engl J Med. 2005 Mar 10;352(10):987-96
references.pmid: 15758009
references.citation: Clin Cancer Res. 2005 Feb 15;11(4):1462-6
references.pmid: 15746047